452 related articles for article (PubMed ID: 24819643)
21. Genotyping for severe drug hypersensitivity.
Karlin E; Phillips E
Curr Allergy Asthma Rep; 2014 Mar; 14(3):418. PubMed ID: 24429903
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetic information derived from analysis of HLA alleles.
Gatanaga H; Honda H; Oka S
Pharmacogenomics; 2008 Feb; 9(2):207-14. PubMed ID: 18370849
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics of allopurinol--making an old drug safer.
Lam MP; Yeung CK; Cheung BM
J Clin Pharmacol; 2013 Jul; 53(7):675-9. PubMed ID: 23381951
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics of hypersensitivity drug reactions.
Negrini S; Becquemont L
Therapie; 2017 Apr; 72(2):231-243. PubMed ID: 28162244
[TBL] [Abstract][Full Text] [Related]
25. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children.
Manuyakorn W; Likkasittipan P; Wattanapokayakit S; Suvichapanich S; Inunchot W; Wichukchinda N; Khongkhatithuml C; Thampratankul L; Kamchaisatian W; Benjaponpitak S; Mahasirimongkol S
Epilepsy Res; 2020 May; 162():106321. PubMed ID: 32272329
[TBL] [Abstract][Full Text] [Related]
26. HLA and pharmacogenetics of drug hypersensitivity.
Pavlos R; Mallal S; Phillips E
Pharmacogenomics; 2012 Aug; 13(11):1285-306. PubMed ID: 22920398
[TBL] [Abstract][Full Text] [Related]
27. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
28. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
[TBL] [Abstract][Full Text] [Related]
29. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.
Jarjour S; Barrette M; Normand V; Rouleau JL; Dubé MP; de Denus S
Pharmacogenomics; 2015; 16(7):755-67. PubMed ID: 25965122
[TBL] [Abstract][Full Text] [Related]
30. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
[TBL] [Abstract][Full Text] [Related]
31. A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions.
Nguyen DV; Vidal C; Chi HC; Do NTQ; Fulton R; Li J; Fernando SL
HLA; 2017 Dec; 90(6):335-342. PubMed ID: 28884973
[TBL] [Abstract][Full Text] [Related]
32. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population.
Mushiroda T; Takahashi Y; Onuma T; Yamamoto Y; Kamei T; Hoshida T; Takeuchi K; Otsuka K; Okazaki M; Watanabe M; Kanemoto K; Oshima T; Watanabe A; Minami S; Saito K; Tanii H; Shimo Y; Hara M; Saitoh S; Kinoshita T; Kato M; Yamada N; Akamatsu N; Fukuchi T; Ishida S; Yasumoto S; Takahashi A; Ozeki T; Furuta T; Saito Y; Izumida N; Kano Y; Shiohara T; Kubo M;
JAMA Neurol; 2018 Jul; 75(7):842-849. PubMed ID: 29610831
[TBL] [Abstract][Full Text] [Related]
33. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].
Gamba C; Schroeder J; Citterio A; Cazzaniga S; Rivolta AL; Vighi G;
Recenti Prog Med; 2014 Oct; 105(10):379-84. PubMed ID: 25282350
[TBL] [Abstract][Full Text] [Related]
34. New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity.
Michels AW; Ostrov DA
J Allergy Clin Immunol; 2015 Aug; 136(2):252-7. PubMed ID: 26254052
[TBL] [Abstract][Full Text] [Related]
35. Presence of the HLA-A*3101 allele in a familial case of drug reaction with eosinophilia and systemic symptoms, secondary to carbamazepine.
Anjum N; Polak ME; Ardern-Jones M; Cooper HL
Clin Exp Dermatol; 2014 Apr; 39(3):307-9. PubMed ID: 24635066
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology of severe drug hypersensitivity.
Dodiuk-Gad RP; Laws PM; Shear NH
Semin Cutan Med Surg; 2014 Mar; 33(1):2-9. PubMed ID: 25037253
[TBL] [Abstract][Full Text] [Related]
37. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.
White KD; Chung WH; Hung SI; Mallal S; Phillips EJ
J Allergy Clin Immunol; 2015 Aug; 136(2):219-34; quiz 235. PubMed ID: 26254049
[TBL] [Abstract][Full Text] [Related]
38. Adverse cutaneous drug reactions in a single quaternary referral hospital.
Botelho LF; Porro AM; Enokihara MM; Tomimori J
Int J Dermatol; 2016 Apr; 55(4):e198-203. PubMed ID: 26710962
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacogenetics].
Merk HF
Hautarzt; 2010 Aug; 61(8):650-3. PubMed ID: 20644905
[TBL] [Abstract][Full Text] [Related]
40. HLA and drug-induced toxicity.
Phillips EJ; Mallal SA
Curr Opin Mol Ther; 2009 Jun; 11(3):231-42. PubMed ID: 19479656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
